Wockhardt Limited share price
NSE: WOCKPHARMA · ISIN INE049B01025
Key numbers
- Market cap
- ₹ 36,814 Cr
- Current price
- ₹ 2,265.60
- 52-week high / low
- ₹ 2,422 / 1,087
- Stock P/E
- 90.1
- Book value
- ₹ 304.4
- Dividend yield
- 0.00%
- ROCE
- 6.6%
- ROE
- 4.6%
- Debt to equity
- 0.45
- Sales growth (3 yrs)
- 7.8%
- Profit growth (3 yrs)
- -
- 1-year return
- 52.0%
About Wockhardt Limited
Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products. The company also develops its flagship antibiotic, ZAYNICH zidebactam/cefepime, a novel beta lactam enhancer mechanism for the treatment of sepsis and hospital/ventilator associated pneumonia; FOVISCU, an antibiotic for gram-negative infections; MIQNAF nafithromycin, which targets azithromycin-resistant community respiratory pathogens; and ODRATE, a once-daily combination of ertapenem and zidebactam for resistant gram-negative infections through outpatient parenteral antimicrobial therapy. In addition, it develops and commercializes insulin analogs, glucagon-like peptide-1 agonists, and novel combination drug products; Biovac-B, a recombinant hepatitis-B vaccine; Wepox, a recombinant human erythropoietin; Wosulin, a recombinant human insulin; and Glaritus, a recombinant insulin glargine, as well as offers insulin aspart regular and biphasic drug products. Further, the company offers delivery…
Quarterly results
Consolidated figures in ₹ crores
| Mar 2025 | Jun 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 743 | 738 | 888 | 965 | 929 |
| Operating profit | 79 | 101 | 173 | 196 | 188 |
| Net profit | -25 | -90 | 59 | 166 | 106 |
| EPS (₹) | -1.57 | -5.53 | 3.61 | 10.23 | 6.55 |
Peers in Drug Manufacturers - Specialty & Generic
Data for information only, not investment advice. Prices end of day.